ATE237346T1 - Gebrauch von galanin um nervenschäden zu reparieren - Google Patents
Gebrauch von galanin um nervenschäden zu reparierenInfo
- Publication number
- ATE237346T1 ATE237346T1 AT97932939T AT97932939T ATE237346T1 AT E237346 T1 ATE237346 T1 AT E237346T1 AT 97932939 T AT97932939 T AT 97932939T AT 97932939 T AT97932939 T AT 97932939T AT E237346 T1 ATE237346 T1 AT E237346T1
- Authority
- AT
- Austria
- Prior art keywords
- galanin
- treatment
- nerve damage
- supression
- pain
- Prior art date
Links
- 208000028389 Nerve injury Diseases 0.000 title abstract 2
- 230000008764 nerve damage Effects 0.000 title abstract 2
- 101800002068 Galanin Proteins 0.000 abstract 5
- 102000019432 Galanin Human genes 0.000 abstract 4
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 abstract 4
- 230000036407 pain Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 206010036832 Prolactinoma Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 238000001949 anaesthesia Methods 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 238000011813 knockout mouse model Methods 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 208000005877 painful neuropathy Diseases 0.000 abstract 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9615551.0A GB9615551D0 (en) | 1996-07-24 | 1996-07-24 | Galanin |
| GBGB9623869.6A GB9623869D0 (en) | 1996-11-15 | 1996-11-15 | Galanin |
| PCT/GB1997/001991 WO1998003059A1 (en) | 1996-07-24 | 1997-07-24 | Galanin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE237346T1 true ATE237346T1 (de) | 2003-05-15 |
Family
ID=26309752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02028584T ATE457125T1 (de) | 1996-07-24 | 1997-07-24 | Verwendung eines galanin-agonisten in der herstellung eines medikaments zur verbesserung des gedächtnisses und anderer cognitiver funktionen |
| AT97932939T ATE237346T1 (de) | 1996-07-24 | 1997-07-24 | Gebrauch von galanin um nervenschäden zu reparieren |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02028584T ATE457125T1 (de) | 1996-07-24 | 1997-07-24 | Verwendung eines galanin-agonisten in der herstellung eines medikaments zur verbesserung des gedächtnisses und anderer cognitiver funktionen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20030009777A1 (de) |
| EP (2) | EP1342410B1 (de) |
| JP (1) | JP2000516212A (de) |
| AT (2) | ATE457125T1 (de) |
| AU (1) | AU3630297A (de) |
| DE (2) | DE69721005T2 (de) |
| DK (2) | DK1342410T3 (de) |
| ES (2) | ES2196349T3 (de) |
| GB (1) | GB2331301C (de) |
| PT (2) | PT1342410E (de) |
| WO (1) | WO1998003059A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6790656B1 (en) | 1996-01-24 | 2004-09-14 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR2 receptors |
| US6329197B2 (en) | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
| JP2005507654A (ja) * | 2001-08-27 | 2005-03-24 | トゥラリック インコーポレイテッド | 増幅した癌遺伝子およびそれらの癌への関与 |
| AU2003211562A1 (en) * | 2002-02-22 | 2003-09-09 | Takeda Chemical Industries, Ltd. | Novel dna and use thereof |
| GB0403509D0 (en) * | 2004-02-17 | 2004-03-24 | Neuro Targets Ltd | Galanin receptors and brain injury |
| AU2005299771A1 (en) | 2004-10-21 | 2006-05-04 | High Point Pharmaceuticals, Llc | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use |
| GB0523550D0 (en) | 2005-11-18 | 2005-12-28 | Hunter Fleming Ltd | Therapeutic uses of steroidal compounds |
| AU2008207287A1 (en) * | 2007-01-19 | 2008-07-24 | Howard Florey Institute Of Experimental Physiology And Medicine | Use of galanin in a method of treating neurodegenerative diseases or conditions |
| US20100210568A1 (en) * | 2007-09-11 | 2010-08-19 | Mondobiotech Laboratories Ag | Thyrotropin releasing hormone for therapeutic applications |
| US20100204129A1 (en) * | 2008-09-09 | 2010-08-12 | Dorian Bevec | Use of a peptide as a therapeutic agent |
| ES2883838A1 (es) * | 2020-06-04 | 2021-12-09 | Univ Malaga | Prevencion y/o tratamiento del deterioro cognitivo asociado a sindromes de demencia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992012997A1 (en) | 1991-01-16 | 1992-08-06 | The General Hospital Corporation | Human galanin |
| WO1992015015A1 (en) * | 1991-02-25 | 1992-09-03 | Zymogenetic, Inc. | Methods for detecting galanin antagonists |
| WO1992015681A1 (en) * | 1991-03-06 | 1992-09-17 | Garvan Institute Of Medical Research | HUMAN GALANIN, cDNA CLONES ENCODING HUMAN GALANIN AND A METHOD OF PRODUCING HUMAN GALANIN |
| SE9101472D0 (sv) * | 1991-05-15 | 1991-05-15 | Trion Forskning & Utveckling | Galanin antagonist |
| JPH06172387A (ja) * | 1992-12-11 | 1994-06-21 | Aibaitsu Kk | 合成ペプチド誘導体 |
| US6225282B1 (en) * | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| US6790656B1 (en) * | 1996-01-24 | 2004-09-14 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR2 receptors |
-
1997
- 1997-07-24 PT PT02028584T patent/PT1342410E/pt unknown
- 1997-07-24 DK DK02028584.7T patent/DK1342410T3/da active
- 1997-07-24 ES ES97932939T patent/ES2196349T3/es not_active Expired - Lifetime
- 1997-07-24 DE DE69721005T patent/DE69721005T2/de not_active Expired - Lifetime
- 1997-07-24 US US09/230,463 patent/US20030009777A1/en not_active Abandoned
- 1997-07-24 ES ES02028584T patent/ES2340984T3/es not_active Expired - Lifetime
- 1997-07-24 GB GB9901264A patent/GB2331301C/en not_active Expired - Fee Related
- 1997-07-24 EP EP02028584A patent/EP1342410B1/de not_active Expired - Lifetime
- 1997-07-24 PT PT97932939T patent/PT918455E/pt unknown
- 1997-07-24 DK DK97932939T patent/DK0918455T3/da active
- 1997-07-24 WO PCT/GB1997/001991 patent/WO1998003059A1/en not_active Ceased
- 1997-07-24 DE DE69739760T patent/DE69739760D1/de not_active Expired - Lifetime
- 1997-07-24 AT AT02028584T patent/ATE457125T1/de not_active IP Right Cessation
- 1997-07-24 EP EP97932939A patent/EP0918455B1/de not_active Expired - Lifetime
- 1997-07-24 JP JP10506711A patent/JP2000516212A/ja not_active Ceased
- 1997-07-24 AU AU36302/97A patent/AU3630297A/en not_active Abandoned
- 1997-07-24 AT AT97932939T patent/ATE237346T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000516212A (ja) | 2000-12-05 |
| GB2331301C (en) | 2005-05-22 |
| DE69721005D1 (de) | 2003-05-22 |
| PT1342410E (pt) | 2010-05-11 |
| ES2196349T3 (es) | 2003-12-16 |
| ATE457125T1 (de) | 2010-02-15 |
| GB2331301A (en) | 1999-05-19 |
| DK0918455T3 (da) | 2003-08-04 |
| DE69739760D1 (de) | 2010-03-25 |
| EP1342410A2 (de) | 2003-09-10 |
| EP0918455B1 (de) | 2003-04-16 |
| WO1998003059A1 (en) | 1998-01-29 |
| EP1342410B1 (de) | 2010-02-10 |
| US20030009777A1 (en) | 2003-01-09 |
| GB2331301B (en) | 2001-02-14 |
| EP1342410A3 (de) | 2003-12-10 |
| EP0918455A1 (de) | 1999-06-02 |
| DE69721005T2 (de) | 2004-06-09 |
| AU3630297A (en) | 1998-02-10 |
| DK1342410T3 (da) | 2010-05-31 |
| GB9901264D0 (en) | 1999-03-10 |
| PT918455E (pt) | 2003-09-30 |
| ES2340984T3 (es) | 2010-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| DK1135153T3 (da) | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser | |
| DE60031396D1 (de) | Zubereitung zur behandlung von einer neurologischen erkrankung | |
| DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| DE60035057D1 (de) | CD40 Antagonist zur Behandlung von Psoriasis | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| TR200002773T2 (tr) | Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı. | |
| DE60335244D1 (de) | Behandlung von verletzungen des zentralen nervensystems | |
| BRPI0414277A (pt) | métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2 | |
| BR9811780A (pt) | Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente | |
| BR0015416A (pt) | Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos | |
| ATE237346T1 (de) | Gebrauch von galanin um nervenschäden zu reparieren | |
| EA200200132A1 (ru) | СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ | |
| DE69711078D1 (de) | Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz | |
| BR0012327A (pt) | Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados | |
| FR2825273B1 (fr) | Composition pour le traitement des signes cutanes du vieillissement | |
| ATE326265T1 (de) | Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte | |
| BR0012921A (pt) | Compostos calcilìticos | |
| PT1152757E (pt) | Inibidores de mmp no amolecimento do tecido conjuntivo | |
| BR9713538A (de) | ||
| DE602004016547D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| ATE333287T1 (de) | Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten | |
| DE69941134D1 (de) | Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen | |
| ATE345138T1 (de) | Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen | |
| MXPA02004704A (es) | Analogos de acido hidroxieicosatetraenoico y sus metodos de uso en el tratamiento de trastornos de resequedad del ojo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0918455 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |